UBS AM
CTKB icon

UBS AM’s Cytek Biosciences CTKB Stock Holding History

UBS AM’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.58K Hold
582
– – ﹤0.01% 3503
2026
Q1 		$2.54K Sell
582
-250
-30% -$1.18K ﹤0.01% 3558
2025
Q4 		$4.2K Buy
+832
New +$3.86K ﹤0.01% 3009
2025
Q3 		– Sell
-284,350
Closed -$967K – 2360
2025
Q2 		$967K Buy
284,350
+92,726
+48% +$309K ﹤0.01% 2393
2025
Q1 		$768K Sell
191,624
-5,434
-3% -$28.2K ﹤0.01% 2404
2024
Q4 		$1.28M Buy
197,058
+22,433
+13% +$134K ﹤0.01% 2261
2024
Q3 		$967K Sell
174,625
-24,528
-12% -$139K ﹤0.01% 2413
2024
Q2 		$1.11M Buy
199,153
+75,022
+60% +$451K ﹤0.01% 2323
2024
Q1 		$833K Buy
124,131
+1,015
+0.8% +$8.03K ﹤0.01% 2099
2023
Q4 		$1.12M Buy
123,116
+11,593
+10% +$73K ﹤0.01% 1964
2023
Q3 		$616K Buy
111,523
+47,428
+74% +$380K ﹤0.01% 2204
2023
Q2 		$589K Hold
64,095
– – ﹤0.01% 2254
2023
Q1 		$589K Buy
64,095
+1,063
+2% +$11.4K ﹤0.01% 2254
2022
Q4 		$644K Sell
63,032
-6,790
-10% -$91.3K ﹤0.01% 2068
2022
Q3 		$1.03M Buy
69,822
+5,865
+9% +$76.2K ﹤0.01% 1954
2022
Q2 		$686K Buy
+63,957
New +$637K ﹤0.01% 2156

Other funds holding CTKB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

UBS AM's CTKB Position: Q2 2026 in Review

UBS AM held its Cytek Biosciences (CTKB) position steady in Q2 2026 at 582 shares worth $2.58K. The position accounts for ﹤0.01% of the portfolio, ranked #3503.

UBS AM first reported a position in CTKB in Q2 2022 and has held it in 16 quarters since. The position peaked at $1.28M in Q4 2024. 155 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

  • UBS AM held 582 shares of Cytek Biosciences worth $2.58K as of Q2 2026.
  • UBS AM left its Cytek Biosciences share count unchanged in Q2 2026.
  • Cytek Biosciences made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #3503 holding.
  • UBS AM first reported a position in Cytek Biosciences in Q2 2022 and has held it in 16 quarters since.
  • UBS AM's Cytek Biosciences position peaked at $1.28M in Q4 2024.
  • 155 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.